Form 4: Amphastar Pharmaceuticals CFO William J. Peters Reports Stock and Option Awards
SEC Form 4 Filing
William J. Peters, CFO, EVP & Treasurer of Amphastar Pharmaceuticals, reports the acquisition of restricted stock units and stock options.
Summary
- On March 10, 2025, William J. Peters, CFO, EVP & Treasurer of Amphastar Pharmaceuticals, reported transactions involving the company's stock.
- Peters acquired 36,747 shares of common stock in the form of restricted stock units (RSUs) at $0, which vest in four equal annual installments starting March 10, 2026.
- He also acquired options to purchase 78,039 shares of common stock at an exercise price of $28.41, which vest in four equal annual installments beginning March 10, 2026, and expire on March 10, 2035.
- Following these transactions, Peters directly owns 130,230 shares of common stock and options for 78,039 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it reports routine executive compensation. The grants are positive for incentivizing management, but there are no immediate financial implications.
Positives
- The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
- The vesting schedules for both the RSUs and stock options (starting March 10, 2026) encourage long-term commitment from the CFO.
Industry Context
Stock options and restricted stock units are common forms of executive compensation in the pharmaceutical industry, used to attract and retain talent and align management interests with shareholder value.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, are standard practice among publicly traded pharmaceutical companies.
- Companies like Teva Pharmaceutical Industries Ltd. and Mylan N.V. (now Viatris) also utilize similar equity-based compensation plans for their executives.
- The vesting schedules and exercise prices are generally structured to incentivize long-term performance and align with industry benchmarks for executive compensation.
Stakeholder Impact
- Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
- Employees may see the grants as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 03/10/2025 | Date of transaction: Acquisition of RSUs and stock options. |
| 03/10/2026 | Vesting start date for RSUs and stock options (annual installments). |
| 03/10/2035 | Expiration date for the stock options. |
| 03/12/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.